Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions.
Approximately 7.5 million people in the United States have psoriasis, and the impact of this disease goes far beyond its visible effects on the skin.
Bring the drugs, hold the suds. That summarizes a promising new drug-making technique designed to reduce serious allergic reactions and other side effects from anti-cancer medicine, testosterone and other drugs that are administered with a needle.
The kidney is the most commonly transplanted organ in the United States, with more than 17,000 transplants performed each year. Following kidney transplant, patients are routinely placed on a regimen of immunosuppressant medications to prevent organ rejection, which often includes calcineurin inhibitors (CNIs) as the backbone medication of this regimen.
A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients.
A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.
Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).
Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.
The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).
Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.
Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research.
Six hot line sessions at ESC Congress 2015 are set to reveal the latest in cardiovascular disease research across a range of conditions and comorbidities. Hot topics include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease.
Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.
Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults.
New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).
Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price.